Nutrasource announces that Kelai Pharmaceutical, has chosen the global full-service contract research organisation (CRO) to support and strategically manage its early stage drug development programme
“Navigating the regulatory pathway for a new drug is no simple task,” notes Dr Jacqueline Jacques, CEO, Kelai Pharmaceutical.
“Kelai is happy to have an FDA regulatory partner with significant expertise in both natural compounds and pharmaceuticals to support us in plotting this course. This will let us be laser-focused on the most important tasks – minimising our risk and optimising our efforts from the earliest stages of development.”
Botanicals represent unique pharmaceutical opportunities because they start out as very complex endogenous compounds, and many different aspects of the plant might produce the eventual drug candidate.
Navigating this journey in a very targeted manner is mission critical. Although the medicinal properties of botanicals are often well known, they have not been developed in a pharmaceutical context, which is both a challenge and an opportunity.
“Nutrasource’s longstanding strategic positions in both nutrition and pharmaceutical scientific solutions were key factors in Kelai’s decision making process,” says William Rowe, President, and CEO of Nutrasource.
“We are delighted to be serving Dr. Jacques and her team in this capacity, bringing cutting edge botanicals and related technology down the pharmaceutical pathway.”